Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

TetraLogic Pharmaceuticals Granted Third U.S. Patent on Birinapant

TetraLogic Pharmaceuticals
Posted on: 09 Oct 12

TetraLogic Pharmaceuticals today announced that the U.S. Patent and Trademark Office issued a third patent with claims that cover birinapant, a Smac mimetic currently in Phase 2 clinical studies for the treatment of various cancers. U.S. patent number 8,283,372 has claims directed specifically to birinapant as a new chemical entity (NCE) and to drug products comprising birinapant. The patent extends TetraLogic’s birinapant patent estate in the United States to June 2030, with potential for extension pursuant to the Hatch-Waxman Act. Counterpart patent applications are pending examination in Europe, Japan, China, and other major and emerging markets.

Two earlier-issued patents, U.S. 7,517,906 and U.S. 8,022,230, have claims directed to a class of compounds that includes birinapant.

About Birinapant

Birinapant (formerly TL32711) is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases), an endogenous regulator of apoptotic cell death that selectively antagonizes multiple Inhibitor of Apoptosis Proteins (IAPs). Birinapant is in Phase 2 clinical development for solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing. In the clinical studies to date, birinapant has been well tolerated and exhibited rapid suppression of IAPs and antitumor activity as a single agent and in combination with standard-of-care chemotherapies.

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company’s institutional investors include Clarus Ventures, HealthCare Ventures, Quaker Partners, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company’s Web site at www.tetralogicpharma.com.

Business Wire
http://www.businesswire.com/

Last updated on: 09/10/2012

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.